Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
UCB will add the investigational candidate zilucoplan to its therapeutic pipeline for the treatment of people with myasthenia gravis (MG), after announcing it will acquire the therapy’s developer, Ra ... Read more
The use of blood cholesterol-lowering medications called statins is linked to a small risk of myasthenia gravis (MG), according to a large World Health Organization database study. The study, ... Read more
People with myasthenia gravis can develop psychiatric symptoms, including depression and insomnia. However, recommendations regarding safe medication are insufficient. In this case study, clinicians suggest that alpha-blockers are a ... Read more
A new extended release formulation of zilucoplan, a potential self-administered therapy for patients with generalized myasthenia gravis (gMG), given once weekly, achieved complement 5 (C5) inhibition similarly to zilucoplan administered daily, ... Read more
Although rare, myasthenia gravis can develop in patients with systemic lupus erythematosus, according to a case study. The study, “Systemic Lupus Erythematosus and Myasthenia Gravis: A Rare Association,” was published ... Read more
A small regulatory RNA, called microRNA-653, inhibited the proliferation of thymus cells, called thymocytes, in a mouse model of myasthenia gravis (MG), a study reports. Given that the thymus ... Read more
Topline results from a Phase 2 trial of Ra Pharma’s zilucoplan (previously known as RA101495), a potential self-administered therapy for patients with generalized myasthenia gravis (MG), showed a statistically significant decrease ... Read more